{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:50:37Z","timestamp":1791453037186,"version":"4.3.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00663-5","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:30:51Z","timestamp":1791174651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BAY-876 restores lenvatinib sensitivity in resistant hepatocellular carcinoma cells by disrupting the GLUT1\u2013SLC7A11\u2013NADPH redox axis"],"prefix":"10.1007","volume":"34","author":[{"given":"Ranran","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"3","key":"663_CR1","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00428-025-04301-4","volume":"488","author":"K Dimopoulou","year":"2019","unstructured":"Dimopoulou K, Myoteri D, Contis J, Lykoudis P, Nastos C, Fragulidis G, et al. Central histopathological review of a European hepatocellular carcinoma cohort: impact of the WHO 2019 classification on histological diagnosis and TNM staging. Virchows Arch. 2019;488(3):639\u201349.","journal-title":"Virchows Arch"},{"key":"663_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001678","author":"W Ding","year":"2026","unstructured":"Ding W, Wu J, Dou J, Liu F, Han Z, Yu J, et al. Biologically explicable multimodal model predicting local tumor progression and tumor invasiveness of hepatocellular carcinoma. Hepatology. 2026. https:\/\/doi.org\/10.1097\/HEP.0000000000001678.","journal-title":"Hepatology"},{"issue":"1","key":"663_CR3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317801121","volume":"122","author":"W Shi","year":"2025","unstructured":"Shi W, Yi X, Ruan H, Wang D, Wu D, Jiang P, et al. An animal model recapitulates human hepatic diseases associated with GATA6 mutations. Proc Natl Acad Sci U S A. 2025;122(1):e2317801121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"663_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70059","volume":"5","author":"B Hu","year":"2025","unstructured":"Hu B, Gao Q. Global advances in hepatocellular carcinoma research and therapy in 2025. Cancer Innov. 2025;5(2):e70059.","journal-title":"Cancer Innov"},{"issue":"1","key":"663_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52413-9","volume":"14","author":"J Zhou","year":"2024","unstructured":"Zhou J, Li H, Wu B, Zhu L, Huang Q, Guo Z, et al. Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer. Sci Rep. 2024;14(1):1860.","journal-title":"Sci Rep"},{"issue":"6","key":"663_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Syed YY, Scott LJ, Lenvatinib. A Review in Hepatocellular Carcinoma: ZT Al-Salama et al. Drugs. 2019;79(6):665\u201374.","journal-title":"Drugs"},{"key":"663_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117488","author":"H Yang","year":"2025","unstructured":"Yang H, Chen X, Huang S, Dai H, Xiao Z, Fan J, et al. A novel GSH depletor for simultaneous ferroptosis and cuproptosis activation in hepatocellular carcinoma. Biochem Pharmacol. 2025. https:\/\/doi.org\/10.1016\/j.bcp.2025.117488.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"663_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.hbpd.2018.12.006","volume":"18","author":"C Xue","year":"2019","unstructured":"Xue C, Ren Z, Hu X, He Y, Sun R, Li J, et al. The successful treatment for cardiac tamponade during radiofrequency ablation of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2019;18(1):90\u20132.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"9","key":"663_CR9","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2174\/0109298665330781240830042601","volume":"31","author":"W Ye","year":"2024","unstructured":"Ye W, Wang J, Zheng J, Jiang M, Zhou Y, Wu Z. Association between higher expression of Vav1 in hepatocellular carcinoma and unfavourable clinicopathological features and prognosis. Protein Pept Lett. 2024;31(9):706\u201313.","journal-title":"Protein Pept Lett"},{"key":"663_CR10","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429260902230925044009","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Gu J, Yu H, Chen F, Long C, Maihemuti M, et al. Screening and identification of esr1 as a target of icaritin in hepatocellular carcinoma: evidence from bibliometrics and bioinformatic analysis. Curr Mol Pharmacol. 2023. https:\/\/doi.org\/10.2174\/0118761429260902230925044009.","journal-title":"Curr Mol Pharmacol"},{"issue":"4","key":"663_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cpan.2025.04.001","volume":"21","author":"G Ge","year":"2025","unstructured":"Ge G, Jiang X, Tian X, Zhou Y, Cao G. The role of Salvia miltiorrhiza compounds in hepatocellular carcinoma: a preliminary investigation based on computational analysis and liquid chromatography-tandem mass spectrometry. Curr Pharm Anal. 2025;21(4):249\u201364.","journal-title":"Curr Pharm Anal"},{"issue":"3","key":"663_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1515\/oncologie-2025-0512","volume":"28","author":"Y Zou","year":"2026","unstructured":"Zou Y, Ying L, Zhang S, Wang J, Liu Y, Zhong J, et al. Metabolic reprogramming and its implications for drug resistance in colorectal cancer. Oncologie. 2026;28(3):497\u2013512.","journal-title":"Oncologie"},{"issue":"3","key":"663_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s12276-025-01415-2","volume":"57","author":"S Park","year":"2025","unstructured":"Park S, Hall MN. Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications. Exp Mol Med. 2025;57(3):515\u201323.","journal-title":"Exp Mol Med"},{"issue":"10","key":"663_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41388-023-02593-x","volume":"42","author":"ZC Nwosu","year":"2023","unstructured":"Nwosu ZC, Song MG, di Magliano MP, Lyssiotis CA, Kim SE. Nutrient transporters: connecting cancer metabolism to therapeutic opportunities. Oncogene. 2023;42(10):711\u201324.","journal-title":"Oncogene"},{"issue":"2","key":"663_CR15","first-page":"756","volume":"32","author":"RS El Yamany","year":"2026","unstructured":"El Yamany RS, El-Shal AS, Abdelbary EH, Abdelhamid MI, Haggag R, Sarhan WM. Interplay Between GLUT1 Expression and the Long Non-Coding RNA NEAT1 in Breast Cancer. Zagazig Univ Med J. 2026;32(2):756\u201370.","journal-title":"Zagazig Univ Med J"},{"key":"663_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celbio.2026.100367","author":"W Yang","year":"2026","unstructured":"Yang W, Wu Z, Ouyang R, Dai C, Xu Y, Wang H, et al. In vivo magnetic resonance imaging of glucose via interfacial enzyme-catalyzed signal-amplifying probes. Cell Biomaterials. 2026. https:\/\/doi.org\/10.1016\/j.celbio.2026.100367.","journal-title":"Cell Biomaterials"},{"key":"663_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2026.1715716","volume":"14","author":"L Gan","year":"2026","unstructured":"Gan L, Li Q, Yu B, Si J, Li Q, Chen W, et al. Glucose metabolic reprogramming: a novel strategy to enhance radiotherapy response to triple-negative breast cancer. Front Public Health. 2026;14:1715716.","journal-title":"Front Public Health"},{"issue":"10","key":"663_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101429","volume":"10","author":"L Kennedy","year":"2020","unstructured":"Kennedy L, Sandhu JK, Harper M-E, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10(10):1429.","journal-title":"Biomolecules"},{"key":"663_CR19","unstructured":"Sutton SO. Exploring the Role of Astrocyte System XC\u2013in Excitatory\/Inhibitory Balance. Syracuse University; 2025."},{"key":"663_CR20","doi-asserted-by":"publisher","first-page":"117163","DOI":"10.1016\/j.biopha.2024.117163","volume":"177","author":"J He","year":"2024","unstructured":"He J, Feng X, Liu Y, Wang Y, Ge C, Liu S, et al. Graveoline attenuates D-GalN\/LPS-induced acute liver injury via inhibition of JAK1\/STAT3 signaling pathway. Biomed Pharmacother. 2024;177:117163.","journal-title":"Biomed Pharmacother"},{"key":"663_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.858462","volume":"12","author":"N Jyotsana","year":"2022","unstructured":"Jyotsana N, Ta KT, DelGiorno KE. The role of cystine\/glutamate antiporter SLC7A11\/xCT in the pathophysiology of cancer. Front Oncol. 2022;12:858462.","journal-title":"Front Oncol"},{"key":"663_CR22","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S569536","author":"S Hu","year":"2026","unstructured":"Hu S, Wang Y, Tian G, Qiu Z. The dual role of SLC7A11 in colorectal cancer ferroptosis: from molecular mechanisms to therapeutic opportunities. OncoTargets Ther. 2026. https:\/\/doi.org\/10.2147\/OTT.S569536.","journal-title":"OncoTargets Ther"},{"key":"663_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1559423","volume":"13","author":"W-W Zhu","year":"2025","unstructured":"Zhu W-W, Liu Y, Yu Z, Wang H-Q. SLC7A11-mediated cell death mechanism in cancer: a comparative study of disulfidptosis and ferroptosis. Front Cell Dev Biol. 2025;13:1559423.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"663_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.32604\/or.2026.076406","volume":"34","author":"W Zhao","year":"2026","unstructured":"Zhao W, Wang Q, Zhang J. Disulfidptosis: a metabolic cell death mechanism with therapeutic potential in cancer. Oncol Res. 2026;34(4):12.","journal-title":"Oncol Res"},{"key":"663_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2026.1772310","volume":"13","author":"Q Shi","year":"2026","unstructured":"Shi Q, Liu Y, Xuan M, Fu L, Lou N, Lv C, et al. Recent advances in m6A RNA modification in hepatocellular carcinoma: from mechanisms to therapeutic potential. Front Mol Biosci. 2026;13:1772310.","journal-title":"Front Mol Biosci"},{"issue":"10","key":"663_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/14796694.2026.2651375","volume":"22","author":"T Yau","year":"2026","unstructured":"Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, et al. A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer). Future oncology (London, England). 2026;22(10):1135\u201352.","journal-title":"Future oncology (London, England)"},{"key":"663_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1097277","volume":"14","author":"L Jiang","year":"2023","unstructured":"Jiang L, Li L, Liu Y, Zhan M, Lu L, Yuan S. Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Front Pharmacol. 2023;14:1097277.","journal-title":"Front Pharmacol"},{"key":"663_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1153991","volume":"14","author":"W Bo","year":"2023","unstructured":"Bo W, Chen Y. Lenvatinib resistance mechanism and potential ways to conquer. Front Pharmacol. 2023;14:1153991.","journal-title":"Front Pharmacol"},{"key":"663_CR29","doi-asserted-by":"crossref","unstructured":"Meng Z, Tian E, Hu W, Ren C, Li J. Direct targeting of GLUT1 in cancer: A decade of inhibitor discovery and medicinal chemistry insights. Med Chem Res. 2026:1\u201324.","DOI":"10.1007\/s00044-025-03514-1"},{"key":"663_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.963066","volume":"13","author":"G Gauthier-Coles","year":"2022","unstructured":"Gauthier-Coles G, Br\u00f6er A, McLeod MD, George AJ, Hannan RD, Br\u00f6er S. Identification and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells. Front Pharmacol. 2022;13:963066.","journal-title":"Front Pharmacol"},{"key":"663_CR31","doi-asserted-by":"publisher","first-page":"942064","DOI":"10.3389\/fonc.2022.942064","volume":"12","author":"L Lv","year":"2022","unstructured":"Lv L, Yang S, Zhu Y, Zhai X, Li S, Tao X, et al. Relationship between metabolic reprogramming and drug resistance in breast cancer. Front Oncol. 2022;12:942064.","journal-title":"Front Oncol"},{"key":"663_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-026-04914-4","author":"N Hemmati","year":"2026","unstructured":"Hemmati N, Mozaffari S, Anoush M, Kiasari BA. Mechanistic insights into disulfidptosis in cancer and therapeutic opportunities. Discov Oncol. 2026. https:\/\/doi.org\/10.1007\/s12672-026-04914-4.","journal-title":"Discov Oncol"},{"issue":"1","key":"663_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03538-4","volume":"16","author":"R Chen","year":"2025","unstructured":"Chen R, You J, Weng S, Zhao T. Disulfidptosis mechanisms and therapeutic implications in cancer metabolic reprogramming and future perspectives. Discov Oncol. 2025;16(1):1814.","journal-title":"Discov Oncol"},{"key":"663_CR34","volume":"1","author":"Q Li","year":"2025","unstructured":"Li Q, Wu S, Zhuang L, Gan B. Disulfidptosis and its emerging relevance in cancer and immunity. Ferroptosis and oxidative stress. 2025;1:202506.","journal-title":"Ferroptosis and oxidative stress"},{"issue":"7","key":"663_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202408789","volume":"12","author":"J Wang","year":"2025","unstructured":"Wang J, Chen J, Fan K, Wang M, Gao M, Ren Y, et al. Inhibition of endoplasmic reticulum stress cooperates with SLC7A11 to promote disulfidptosis and suppress tumor growth upon glucose limitation. Adv Sci. 2025;12(7):2408789.","journal-title":"Adv Sci"},{"issue":"39","key":"663_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202408556","volume":"12","author":"Z Song","year":"2025","unstructured":"Song Z, Yao Q, Huang L, Cui D, Xie J, Wu L, et al. Glucose deprivation-induced disulfidptosis via the SLC7A11\u2010INF2 axis: pan\u2010cancer prognostic exploration and therapeutic validation. Adv Sci. 2025;12(39):e08556.","journal-title":"Adv Sci"},{"issue":"4","key":"663_CR37","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41556-020-0496-x","volume":"22","author":"X Liu","year":"2020","unstructured":"Liu X, Olszewski K, Zhang Y, Lim EW, Shi J, Zhang X, et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat Cell Biol. 2020;22(4):476\u201386.","journal-title":"Nat Cell Biol"},{"key":"663_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102649","author":"P Koppula","year":"2021","unstructured":"Koppula P, Olszewski K, Zhang Y, Kondiparthi L, Liu X, Lei G, et al. KEAP1 deficiency drives glucose dependency and sensitizes lung cancer cells and tumors to GLUT inhibition. iScience. 2021. https:\/\/doi.org\/10.1016\/j.isci.2021.102649.","journal-title":"iScience"},{"key":"663_CR39","first-page":"NA","volume":"12","author":"Z Ruan","year":"2026","unstructured":"Ruan Z, Sun X. Metabolic reprogramming and the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic targeting. Hepatoma Res. 2026;12:NA\u2013NA.","journal-title":"Hepatoma Res"},{"key":"663_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1392241","volume":"15","author":"X Li","year":"2011","unstructured":"Li X, Zhou L, Xu X, Liu X, Wu W, Feng Q, et al. Metabolic reprogramming in hepatocellular carcinoma: a bibliometric and visualized study from 2011 to 2023. Front Pharmacol. 2011;15:1392241.","journal-title":"Front Pharmacol"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00663-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00663-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00663-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:02:52Z","timestamp":1791450172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00663-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["663"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00663-5","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"87"}}